It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause.
Clearing proteins, such as amyloid and tau, was... Read more »
Professor of Systems Biology, Columbia University
Managing Partner at Pappas Ventures
Director, Life Sciences Institute, University of Michigan
CEO and Fund Manager, Renaissance Venture Capital Fund
Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina
Co-Founder, BuddyTV
Managing director, the Foundry Group
VP of Research and Special Initiatives, Google
It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause.
Clearing proteins, such as amyloid and tau, was... Read more »
[Corrected 12:27 p.m. See below.] The FDA has rejected an experimental regenerative therapy that Enzyvant developed to restore immune system function in babies born with a rare disorder. The agency cited manufacturing issues, according to the company.
Enzyvant received... Read more »
[Updated 12/4/19, 4:01 p.m. ET. See below.] Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities.
South San Francisco-based Veracyte (NASDAQ: VCYT) announced Tuesday... Read more »
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
As the Federal Trade Commission reviewed Bristol’s (NYSE:... Read more »
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The move—which was announced at the China International... Read more »
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
The AstraZeneca (NYSE: AZN) site in Macclesfield,... Read more »
The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them.
Amgen (NASDAQ: AMGN) is ending its research and early development... Read more »
Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study.
The FDA put a partial clinical hold on a Phase 1/2 study testing the... Read more »
Earlier this year, it seemed that companies testing Alzheimer’s disease treatments based on a long-held hypothesis as to its cause—brain deposits of a protein called beta amyloid—were giving up the ghost.
Biogen (NASDAQ: BIIB) was among them. The drug maker... Read more »
New brand-name drugs typically grab the life science headlines. A venture capital firm will invest tens of millions to develop one and a pharmaceutical company hopes to recoup hundreds of millions by selling it. But a shortage of one particular chemotherapy... Read more »
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan... Read more »
Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about... Read more »
Sixteen years ago, Kim Witczak’s husband died by his own hand, turning her world upside down. He had just begun taking an antidepressant off-label for insomnia, and she believes an undisclosed side effect of the drug drove him to suicide. Compelled... Read more »
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively.
That opening to biotech startups in 2014 was controversial at the... Read more »
Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential treatments for anemia, cancer, and more—and today, it has turned... Read more »
This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.
About a month ago, Precision—a drug and diagnostic developer that’s focused, as... Read more »
It’s been a strange up and down ride for PARP inhibitors, a relatively new class of cancer drugs.
Named for the tumor protein they target, PARPs rebounded after a big clinical setback in 2011 and have been at the center of... Read more »
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
XconomyCEO of the Marine Bio-Technologies Center of Innovation
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Managing Partner at Pappas Ventures
Retired CEO of ShopperTrak RCT Corporation
Founder and CEO of Brooks Bell Inc.
Vice Provost and Director of the Innovation and Entrepreneurship Initiative at Duke University
CEO and co-founder of BoostSuite
Professor at the University of North Carolina at Chapel Hill
Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina
President of the Council for Economic Development (CED)
CEO of G1 Therapeutics